Leukaemia (lymphocytic) - fludarabine

Summary

This guidance has been replaced by TA119 Leukaemia (lymphocytic) - fludarabine

Documents

For healthcare professionals

• TA29 Leukaemia (lymphocytic) - fludarabine: Summary
• TA29 Leukaemia (lymphocytic) - fludarabine: Guidance (html)
• TA29 Leukaemia (lymphocytic) - fludarabine: Guidance

For patients, carers and the public

• TA29 Leukaemia (lymphocytic) - fludarabine: Information for the public

Background information

• Review decision
• Review proposal
• Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Cost-effectiveness annexe
• Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Effectiveness annexe
• Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia - HTA report (main)
• 2001/31 NICE issues guidance on chemotherapy agents for breast cancer and leukaemia

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

• None found